Hasil Pencarian - Gilles Defer

  • Menampilkan 1 - 13 hasil dari 13
Perbaiki Hasil
  1. 1
    Natalizumab in Multiple Sclerosis Treatment: From Biological Effects to Immune Monitoring

    Natalizumab in Multiple Sclerosis Treatment: From Biological Effects to Immune Monitoring oleh Kathy Khoy, Delphine Mariotte, Gilles Defer, Gilles Defer, Gilles Defer, Gautier Petit, Olivier Toutirais, Olivier Toutirais, Olivier Toutirais, Brigitte Le Mauff, Brigitte Le Mauff, Brigitte Le Mauff

    Diterbitkan 2020-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    The Effect of Disease-Modifying Drugs on Brain Atrophy in Relapsing-Remitting Multiple Sclerosis: A Meta-Analysis.

    The Effect of Disease-Modifying Drugs on Brain Atrophy in Relapsing-Remitting Multiple Sclerosis: A Meta-Analysis. oleh Pierre Branger, Jean-Jacques Parienti, Maria Pia Sormani, Gilles Defer

    Diterbitkan 2016-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Socio-economic status influences access to second-line disease modifying treatment in Relapsing Remitting Multiple Sclerosis patients.

    Socio-economic status influences access to second-line disease modifying treatment in Relapsing Remitting Multiple Sclerosis patients. oleh Floriane Calocer, Olivier Dejardin, Karine Droulon, Guy Launoy, Gilles Defer

    Diterbitkan 2018-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    Neuropsychological management of multiple sclerosis: evaluation of a supervised and customized cognitive rehabilitation program for self-used at home (SEPIA): protocol for a randomized controlled trial

    Neuropsychological management of multiple sclerosis: evaluation of a supervised and customized cognitive rehabilitation program for self-used at home (SEPIA): protocol for a random... oleh Caroline Harand, France Daniel, Audrey Mondou, Damien Chevanne, Christian Creveuil, Gilles Defer

    Diterbitkan 2019-10-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    Dedicated mobile application for drug adverse reaction reporting by patients with relapsing remitting multiple sclerosis (Vigip-SEP study): study protocol for a randomized controlled trial

    Dedicated mobile application for drug adverse reaction reporting by patients with relapsing remitting multiple sclerosis (Vigip-SEP study): study protocol for a randomized controll... oleh Gilles Defer, Florian Le Caignec, Sophie Fedrizzi, François Montastruc, Damien Chevanne, Jean-Jacques Parienti, Laure Peyro-Saint-Paul

    Diterbitkan 2018-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    Expert Narrative Review of the Safety of Cladribine Tablets for the Management of Relapsing Multiple Sclerosis

    Expert Narrative Review of the Safety of Cladribine Tablets for the Management of Relapsing Multiple Sclerosis oleh Pierre Clavelou, Giovanni Castelnovo, Valérie Pourcher, Jerome De Sèze, Patrick Vermersch, Ali-Frederic Ben-Amor, Carine Savarin, Gilles Defer

    Diterbitkan 2023-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    Correction: Expert Narrative Review of the Safety of Cladribine Tablets for the Management of Relapsing Multiple Sclerosis

    Correction: Expert Narrative Review of the Safety of Cladribine Tablets for the Management of Relapsing Multiple Sclerosis oleh Pierre Clavelou, Giovanni Castelnovo, Valérie Pourcher, Jerome De Sèze, Patrick Vermersch, Ali-Frederic Ben-Amor, Carine Savarin, Gilles Defer

    Diterbitkan 2023-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  8. 8
    Cognitive Impairment in Secondary Progressive Multiple Sclerosis: Effect of Disease Duration, Age, and Progressive Phenotype

    Cognitive Impairment in Secondary Progressive Multiple Sclerosis: Effect of Disease Duration, Age, and Progressive Phenotype oleh Bruno Brochet, Pierre Clavelou, Gilles Defer, Jérôme De Seze, Céline Louapre, Eloi Magnin, Aurélie Ruet, Catherine Thomas-Anterion, Patrick Vermersch

    Diterbitkan 2022-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  9. 9
    Patient Preference for Subcutaneous Versus Intravenous Administration with Every-6-Week Natalizumab (Tysabri®) Dosing: NOVA Phase IIIb Extension Study (Part 2)

    Patient Preference for Subcutaneous Versus Intravenous Administration with Every-6-Week Natalizumab (Tysabri®) Dosing: NOVA Phase IIIb Extension Study (Part 2) oleh Heinz Wiendl, John Foley, Gilles Defer, Lana Zhovtis Ryerson, Jeffrey A. Cohen, Douglas L. Arnold, Helmut Butzkueven, Gary R. Cutter, Gavin Giovannoni, Joep Killestein, Rose Domingo-Horne, Marie Toukam, Aimie Nunn, Amir-Hadi Maghzi, Robert Kuhelj, Tyler Lasky

    Diterbitkan 2024-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  10. 10
    The Place of Immune Reconstitution Therapy in the Management of Relapsing Multiple Sclerosis in France: An Expert Consensus

    The Place of Immune Reconstitution Therapy in the Management of Relapsing Multiple Sclerosis in France: An Expert Consensus oleh Jerome De Sèze, Laurent Suchet, Claude Mekies, Eric Manchon, Pierre Labauge, Anne-Marie Guennoc, Gilles Defer, Pierre Clavelou, Giovanni Castelnovo, Bertrand Bourre, Caroline Bensa-Koscher, Abdullatif Al Khedr, Julie Le Mao, Lauriane Villemur, Stephane Bouée, Laura Luciani, Patrick Vermersch

    Diterbitkan 2022-12-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  11. 11
    Excess Mortality in Patients with Multiple Sclerosis Starts at 20 Years from Clinical Onset: Data from a Large-Scale French Observational Study.

    Excess Mortality in Patients with Multiple Sclerosis Starts at 20 Years from Clinical Onset: Data from a Large-Scale French Observational Study. oleh Emmanuelle Leray, Sandra Vukusic, Marc Debouverie, Michel Clanet, Bruno Brochet, Jérôme de Sèze, Hélène Zéphir, Gilles Defer, Christine Lebrun-Frenay, Thibault Moreau, Pierre Clavelou, Jean Pelletier, Eric Berger, Philippe Cabre, Jean-Philippe Camdessanché, Shoshannah Kalson-Ray, Christian Confavreux, Gilles Edan

    Diterbitkan 2015-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  12. 12
    Real-World Effectiveness of Natalizumab Extended Interval Dosing in a French Cohort

    Real-World Effectiveness of Natalizumab Extended Interval Dosing in a French Cohort oleh Juliette Pelle, Anais R. Briant, Pierre Branger, Nathalie Derache, Charlotte Arnaud, Christine Lebrun-Frenay, Mikael Cohen, Lydiane Mondot, Jerome De Seze, Kevin Bigaut, Nicolas Collongues, Laurent Kremer, Damien Ricard, Flavie Bompaire, Charlotte Ohlmann, Magali Sallansonnet-Froment, Jonathan Ciron, Damien Biotti, Beatrice Pignolet, Jean-Jacques Parienti, Gilles Defer

    Diterbitkan 2023-02-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  13. 13
    Effects of socioeconomic status on excess mortality in patients with multiple sclerosis in France: A retrospective observational cohort studyResearch in context

    Effects of socioeconomic status on excess mortality in patients with multiple sclerosis in France: A retrospective observational cohort studyResearch in context oleh Sarah Wilson, Floriane Calocer, Fabien Rollot, Mathieu Fauvernier, Laurent Remontet, Laure Tron, Sandra Vukusic, Emmanuelle Le Page, Marc Debouverie, Jonathan Ciron, Aurélie Ruet, Jérôme De Sèze, Hélène Zephir, Thibault Moreau, Christine Lebrun-Frénay, David-Axel Laplaud, Pierre Clavelou, Pierre Labauge, Eric Berger, Jean Pelletier, Olivier Heinzlef, Eric Thouvenot, Jean Philippe Camdessanché, Emmanuelle Leray, Olivier Dejardin, Gilles Defer

    Diterbitkan 2023-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: